North American Experience With the Perma-Flow Prosthetic Coronary Graft

Emery, Robert W.; Mills, Noel L.; Teijeira, F. Javier; Arom, Kit V.; Baldwin, Pam; Petersen, Rebecca J.; Joyce, Lyle D.; Grinnan, George L.B.; Sussman, Marc; Copeland, Jack G.; Ochsner, John L.; Boyce, Steven W.; Nicoloff, Demétre M.

doi:10.1016/s0003-4975(96)00506-1

Cited by 11 publications

(9 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For bypass surgery, autologous graft material, mainly arteries, is preferable, since it leads to good long‐term results 4. However, for cases with pre‐existing vascular disease or prior surgery, alternative graft materials have to be used 5. While homografts can be used, they are limited in number and only recommended for special indications 6.…”

Section: Introductionmentioning

confidence: 99%

Factorial design optimization and in vivo feasibility of poly(ε‐caprolactone)‐micro‐ and nanofiber‐based small diameter vascular grafts

Nottelet

Pektok

Mandracchia

et al. 2008

J Biomedical Materials Res

141

135

View full text Add to dashboard Cite

Because of the severe increase of mortality by cardiovascular diseases, there has been rising interest among the tissue-engineering community for small-sized blood vessel substitutes. Here we present small diameter vascular grafts made of slow degradable poly(epsilon-caprolactone) nanofibers obtained by electrospinning. The process was optimized by a factorial design approach that led to reproducible grafts with inner diameters of 2 and 4 mm, respectively. Fiber sizes, graft morphology, and the resulting tensile stress and tensile strain values were studied as a function of various parameters in order to obtain optimal vascular grafts for implantation after gamma-sterilization. The influence of polymer concentration, solvent, needle-collector distance, applied voltage, flow rate, and spinning time has been studied. Consequently, an optimized vascular graft was implanted as an abdominal aortic substitute in nine rats for a feasibility study. Results are given following up a 12-week implantation period showing good patency, endothelization, and cell ingrowth.

show abstract

Section: Introductionmentioning

confidence: 99%

Factorial design optimization and in vivo feasibility of poly(ε‐caprolactone)‐micro‐ and nanofiber‐based small diameter vascular grafts

Nottelet

Pektok

Mandracchia

et al. 2008

J Biomedical Materials Res

141

135

View full text Add to dashboard Cite

show abstract

“…Similar reports followed in Europe [7,8]. Emery et al [9] then reported the North American results with the conduit in 1996. Forty patients underwent revascularization with this material between November 1992 and December 1995.…”

Section: Discussionmentioning

confidence: 54%

“…Of the 31 survivors, follow-up angiography demonstrated that 9.5% of coronary anastomoses were occluded, and two distal extensions and resistors were occluded. One graft was occluded completely at 1 year [9]. Experience with eight patients in the Netherlands showed patency of 10 of 11 distal anastomoses at 1 week.…”

Section: Discussionmentioning

confidence: 93%

Treatment of a coronary artery to superior vena cava fistula resulting from early closure of a Possis Perma-Flow graft

Graham

Kells

Sullivan

et al. 1999

Cathet. Cardiovasc. Intervent.

View full text Add to dashboard Cite

“…[7][8][9][10][11][12][13][14]. Sheep were cared for according to the National Health and Medical Research Council's Code of Practice for the Care and Use of Animals for Experimental Purposes (Australian Government Publication Service, 1990).…”

Section: Sheepmentioning

confidence: 99%

“…For instance, the well-known Permaflow vascular graft, manufactured by Possis (Minneapolis, MN) is made of ePTFE. 10 Perhaps the most important disadvantage of ePTFE is its chemical inertness, which makes surface modification (aiming at improving the biocompatibility) very difficult. It is for this reason that we decided to test a polyurethane vascular graft, which was constructed from the "biodurable" poly(carbonate) polyurethane Chronoflex.…”

Section: Introductionmentioning

confidence: 99%

Performance of a polyurethane vascular prosthesis carrying a dipyridamole (Persantin�) coating on its lumenal surface

Aldenhoff

Veen

Woorst

et al. 2000

J. Biomed. Mater. Res.

View full text Add to dashboard Cite

A porous polyurethane vascular prosthesis with an internal diameter of 5 mm was studied. The graft carries a coating of immobilized dipyridamole (Persantin(R)) on the surface of its lumen. Dipyridamole is a potent nontoxic inhibitor of platelet activation/aggregation, and also a strong inhibitor of vascular smooth muscle cell proliferation. The polyurethane material is also known as Chronoflex(R), and already finds use as a vascular access graft. The coated vascular graft was studied in vitro (hemocompatibility, interaction with blood platelets and cultured endothelial cells), as well as in two established in vivo models. In the first in vivo study, coated grafts were implanted in goats, as a bypass of the carotid artery (four animals, eight grafts, length of the graft was approximately 12 cm). Four uncoated grafts were used as controls in otherwise identical experiments. In the second in vivo experiment, eight sheep were used. Each animal received one coated and one uncoated prosthesis as an interposition graft in the carotid artery (length of the graft was 4 cm). The in vitro experiments revealed that the dipyridamole coating has three beneficial effects: reduced thrombogenicity, reduced adherence of blood platelets, and accommodation of a confluent monolayer of endothelial cells. The goat experiments showed patency of the coated grafts in three of the eight cases. The sheep experiments were not useful for the evaluation of the dipyridamole coating because deterioration of the polyurethane material was observed. The in vivo results indicate that the dipyridamole coating may positively influence the patency rate, probably because the coating promotes the growth of an endothelial cell lining. The sheep data show, however, that the limited stability of the Chronoflex(R) material precludes its issue for the construction of permanent small-bore vascular grafts.

show abstract

North American Experience With the Perma-Flow Prosthetic Coronary Graft

Cited by 11 publications

References 20 publications

Factorial design optimization and in vivo feasibility of poly(ε‐caprolactone)‐micro‐ and nanofiber‐based small diameter vascular grafts

Factorial design optimization and in vivo feasibility of poly(ε‐caprolactone)‐micro‐ and nanofiber‐based small diameter vascular grafts

Treatment of a coronary artery to superior vena cava fistula resulting from early closure of a Possis Perma-Flow graft

Performance of a polyurethane vascular prosthesis carrying a dipyridamole (Persantin�) coating on its lumenal surface

Contact Info

Product

Resources

About